Yokukansan Alleviates Cancer Pain by Suppressing Matrix Metalloproteinase-9 in a Mouse Bone Metastasis Model.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
11
2018
revised:
13
04
2019
accepted:
22
04
2019
entrez:
27
6
2019
pubmed:
27
6
2019
medline:
27
6
2019
Statut:
epublish
Résumé
Bone cancer pain control is difficult because it includes various characteristics of pain such as nociceptic and neuropathic pain. In this study, we investigated the effect of yokukansan (YKS), one of the traditional Japanese herbal medicines, on cancer pain in mouse bone metastasis model. Oral administration of YKS significantly alleviated pain behavior measured by quantitative body weight bearing. Furthermore, the pain behavior was also significantly alleviated by intrathecal and intraperitoneal administration of matrix metalloproteinase- (MMP-) 9 inhibitor, but not of MMP-2 inhibitor. MMP-9 expression was significantly elevated in the bone tissue on day 3 after carcinoma cell injection and in the ipsilateral spinal cord on day 7, which was suppressed by YKS administration. Taken together, these results suggest that YKS alleviates cancer pain via suppressing MMP-9 expression in bone metastasis model in mice.
Identifiants
pubmed: 31239855
doi: 10.1155/2019/2956920
pmc: PMC6556276
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2956920Commentaires et corrections
Type : ErratumIn
Références
Clin Adv Hematol Oncol. 2004 May;2(5):295-302
pubmed: 16163196
J Surg Oncol. 2006 Jan 1;93(1):36-42; discussion 42-3
pubmed: 16353179
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):881-5
pubmed: 18243460
Nat Med. 2008 Mar;14(3):331-6
pubmed: 18264108
Nutr Neurosci. 2008 Feb;11(1):41-6
pubmed: 18510802
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1516-20
pubmed: 18558456
Eur J Cancer. 2008 Nov;44(16):2506-17
pubmed: 18723339
Trends Pharmacol Sci. 2009 Jul;30(7):336-40
pubmed: 19523695
Cardiovasc Psychiatry Neurol. 2009;2009:904836
pubmed: 20037727
J Neurosci. 2010 Jun 2;30(22):7613-23
pubmed: 20519536
Brain Res Bull. 2010 Nov 20;83(6):351-5
pubmed: 20813168
Physiol Behav. 2011 Sep 1;104(3):495-502
pubmed: 21620878
Mol Pain. 2012 Mar 25;8:19
pubmed: 22444868
Eur J Pharmacol. 2012 May 15;683(1-3):86-92
pubmed: 22445883
Cancer Control. 2012 Apr;19(2):92-101
pubmed: 22487971
Neuroscience. 2012 Dec 27;227:336-49
pubmed: 23069764
Pain. 2013 Dec;154 Suppl 1:S54-62
pubmed: 23916671
Neurosci Lett. 2013 Dec 17;557 Pt A:52-9
pubmed: 24076008
Pharmacology. 2014;93(1-2):47-56
pubmed: 24457951
Curr Pain Headache Rep. 2014 Jun;18(6):423
pubmed: 24760492
Neuropsychiatr Dis Treat. 2014 Sep 12;10:1727-42
pubmed: 25246794
Evid Based Complement Alternat Med. 2015;2015:870687
pubmed: 25866544
Cancer Growth Metastasis. 2015 Aug 23;8(Suppl 1):47-62
pubmed: 26339191
Sci Rep. 2015 Oct 29;5:14648
pubmed: 26511791
Pharmacol Ther. 2016 Oct;166:84-95
pubmed: 27373856
Oncotarget. 2017 Mar 7;8(10):16988-17001
pubmed: 28199982
Pain. 1983 Jun;16(2):109-10
pubmed: 6877845